Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com          SPECIAL REPORT COVID-19     Un point d’étape   Les virus émergents se sont succédés à une fréquence inouïe depuis les vingt dernières années: Virus West Nile en 1999, SARS en 2003, Chinkungunya en 2004, MERS en 2012, Ebola en 2013, […]

  Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com          SPECIAL REPORT #20.27       COVID Treatments (part 3)     Every single biopharmaceutical company is very cautious to assess the benefit-risk ratio of a drug it is going to develop, launch and commercialise across several countries and regions. The […]

  Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com      SPECIAL REPORT #20.26     COVID Treatments (continued)         After weeks of intensive and public struggle between the White House and the the FDA over COVID-19 vaccine guidelines, the US Health agency has released its new vaccine recommendations. On October […]

  Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com       SPECIAL REPORT #20.25     COVID Vaccine Development     We are all waiting with some kind of trepidation final results and positive outcomes from the various COVID vaccines currently in clinical development. Although it was expected that some early validated results […]